Head-to-head evidence
Encorafenib vs HLX208
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: BRAF V600E · full Non-Small Cell Lung Cancer pipeline
Encorafenib
Marketed by Pfizer
NCT03915951 · Phase 2 · completed
The study was open-label, single-group, and had no placebo or active comparator, so the objective response results cannot be directly attributed to the treatment relative to another therapy. Its primary radiographic response endpoint was reported separately for 59 treatment-naive and 39 previously treated participants, but there was no formal between-group primary comparison.
HLX208
Developed by Shanghai Henlius Biotech
NCT05065398 · Phase 2 · status unknown
This is a small, open-label, single-arm study with no control group, so there is no formal comparison to test HLX208's benefit against, and it enrolls only about 20 patients. No results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Encorafenib's landscape · HLX208's landscape